Passage Bio
Philadelphia, United States · Biotechnology, Genetics, Healthcare
Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Philadelphia, United States
- Employees
- 83
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (PASG)
- Website
- passagebio.com
- Company page
Recent activity at Passage Bio
- : SEC 8-K (5.02): On November 5, 2026, Passage Bio, Inc. conducted a Special Meeting of Stockholders where the stockholders approved the 2026 Equity Incentive Plan (the '2026 Plan'), which will replace the existing 2018 and 2020 Equity Incentive Plans and Remix's 2019 Plan, contingent on the completion of the First Merger with Remix Therapeutics, Inc. The 2026 Plan reserves a total of approximately 5,772,500 shares for issuance, with the potential for annual increases beginning January 1, 2027. The plan will also allow for the conversion of outstanding Remix stock options into Passage Bio shares at a predetermined exchange ratio. This transition is significant as it streamlines the stock incentive framework and may impact future compensation strategies for employees of the merged entity.
- : SEC 8-K (1.01): On September 2, 2026, Passage Bio, Inc. entered into an Amended and Restated Merger Agreement with Peregrine Merger Sub, Inc., a wholly owned subsidiary of the Company, and Remix Therapeutics, Inc. This agreement involves a strategic merger designed to advance Passage Bio's capabilities in gene therapy, which is critical for both companies' future product development. The original merger agreement, dated June 24, 2026, lays the foundation for this amendment, enabling Passage Bio to enhance its operational structure and potentially improve market positioning. The merger is subject to specified conditions which if satisfied, could lead to a significant transformation in the combined entities. Details regarding financial terms and implications were not disclosed in this initial filing.
- : Passage Bio to merge with Remix Therapeutics
About Passage Bio: questions and answers
What does Passage Bio do?
Passage Bio, Inc. (NASDAQ: PASG) is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases.
Where is Passage Bio headquartered?
Passage Bio is headquartered in Philadelphia, United States.
How many employees does Passage Bio have?
Passage Bio has about 83 employees.
What is the latest news on Passage Bio?
On Nov 06, 2026, SEC 8-K (5.02): On November 5, 2026, Passage Bio, Inc. conducted a Special Meeting of Stockholders where the stockholders approved the 2026 Equity Incentive Plan (the '2026 Plan'), which will replace the existing 2018 and 2020 Equity Incentive Plans and Remix's 2019 Plan, contingent on the completio
Is Passage Bio a public company?
Yes. Passage Bio is publicly traded under the ticker PASG.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy